PI Institution(s)

Funding source(s)

Partner(s)

Abstract

Intro

To help the market demand for malaria commodities including antimalarial medicines, malaria rapid diagnostic tests (RDTs) and the active pharmaceutical ingredient artemisinin, UNITAID finances and helps coordinate quarterly demand forecasts to inform policy makers and market participants. These forecasts are carried out by the Malaria Diagnostic and Artemisinin Treatment Commodities Forecasting Consortium. All studies are overseen by a Steering Committee composed of representatives from organizations such as UNITAID, the President’s Malaria Initiative, the World Health Organization, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Medicines for Malaria Venture. 

Briefs are also prepared to provide policymakers and other stakeholders with a summary of the latest demand forecasts for antimalarial drugs, RDTs and artemisinin and their implications for health and development policy.

History

At its January 2009 ad hoc meeting in Geneva, the UNITAID Board mandated the UNITAID Secretariat to commission such forecasting services. The Secretariat, recognizing the need to include related activities, broadened the service to include artemisinin and ACT supply and demand forecasting at both the global level and for the Affordable Medicines Facility - malaria (AMFm).  

Since the launch of this project, the quarterly demand forecasts have become a valuable tool in supporting a healthy malaria market by providing insights to policy makers and signals to market participants. 

Global Malaria Diagnostic and Artemisinin Treatment Commodities Demand Forecast, Phase I